259 related articles for article (PubMed ID: 11395138)
1. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
2. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
3. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
4. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
5. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation.
Kovacs H; Campbell ID; Strong P; Johnson S; Ward FJ; Reid KB; Eggleton P
Biochemistry; 1998 Dec; 37(51):17865-74. PubMed ID: 9922153
[TBL] [Abstract][Full Text] [Related]
6. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
7. The binding site for C1q on IgG.
Duncan AR; Winter G
Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
[TBL] [Abstract][Full Text] [Related]
8. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C mu 2, C mu 3, and C mu 4 domains in the regulation of the interaction of IgM with complement C1q.
Chen FH; Arya SK; Rinfret A; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1997 Oct; 159(7):3354-63. PubMed ID: 9317134
[TBL] [Abstract][Full Text] [Related]
9. Binding of the human complement subcomponent C1q to hybrid mouse monoclonal antibodies.
Koolwijk P; Boot JH; Griep R; Bast BJ
Mol Immunol; 1991 Jun; 28(6):567-76. PubMed ID: 1861677
[TBL] [Abstract][Full Text] [Related]
10. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions.
Baudino L; Nimmerjahn F; Shinohara Y; Furukawa J; Petry F; Verbeek JS; Nishimura S; Ravetch JV; Izui S
J Immunol; 2008 Sep; 181(6):4107-12. PubMed ID: 18768867
[TBL] [Abstract][Full Text] [Related]
11. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells.
Michaelsen TE; Thommesen JE; Ihle O; Gregers TF; Sandin RH; Brekke OH; Sandlie I
Eur J Immunol; 2006 Jan; 36(1):129-38. PubMed ID: 16323243
[TBL] [Abstract][Full Text] [Related]
12. Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement.
Sensel MG; Kane LM; Morrison SL
Mol Immunol; 1997 Oct; 34(14):1019-29. PubMed ID: 9488053
[TBL] [Abstract][Full Text] [Related]
13. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.
Tan LK; Shopes RJ; Oi VT; Morrison SL
Proc Natl Acad Sci U S A; 1990 Jan; 87(1):162-6. PubMed ID: 2296577
[TBL] [Abstract][Full Text] [Related]
14. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.
Lucisano Valim YM; Lachmann PJ
Clin Exp Immunol; 1991 Apr; 84(1):1-8. PubMed ID: 1707767
[TBL] [Abstract][Full Text] [Related]
15. [A stable conformer of IgG, prepared by an acidic influence: study by calorimetry, binding of the C1q complement component, and monospecific anti-IgG].
Kravchuk ZI; Vlasov AP; Liakhnovich GV; Martsev SP
Biokhimiia; 1994 Oct; 59(10):1458-77. PubMed ID: 7819387
[TBL] [Abstract][Full Text] [Related]
16. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
17. Atomic resolution model of the antibody Fc interaction with the complement C1q component.
Schneider S; Zacharias M
Mol Immunol; 2012 May; 51(1):66-72. PubMed ID: 22425350
[TBL] [Abstract][Full Text] [Related]
18. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52.
Redpath S; Michaelsen T; Sandlie I; Clark MR
Immunology; 1998 Apr; 93(4):595-600. PubMed ID: 9659234
[TBL] [Abstract][Full Text] [Related]
19. C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids.
Sandlie I; Aase A; Westby C; Michaelsen TE
Eur J Immunol; 1989 Sep; 19(9):1599-603. PubMed ID: 2792180
[TBL] [Abstract][Full Text] [Related]
20. Interaction of C1q With Pentraxin 3 and IgM Revisited: Mutational Studies With Recombinant C1q Variants.
Bally I; Inforzato A; Dalonneau F; Stravalaci M; Bottazzi B; Gaboriaud C; Thielens NM
Front Immunol; 2019; 10():461. PubMed ID: 30923526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
